Literature DB >> 11456019

Recurrences of retinal detachment after vitreoretinal surgery, and surgical approach.

Z Kapran1, O M Uyar, V Kaya, K Eltutar.   

Abstract

PURPOSE: To investigate the causes and management of recurrences of complicated retinal detachment after vitreoretinal surgery.
METHODS: Vitreoretinal surgery was performed in 61 patients with complicated retinal detachment who were followed up for 4-24 (mean 7) months. Liquid perfluorocarbon (PFC) was used in all 61, silicone oil in 40 and perfluoropropane (C3F8) in 18 patients.
RESULTS: Retinal attachment was achieved in 58 patients (95%) during the first operation. Due to the recurrence of detachment 17 patients (29%) had to be operated for a second, 7 (12%) a third and 4 (7%) a fourth time. Anterior and posterior proliferative vitreoretinopathy, missed tear, retinal incarceration, subretinal membrane and perisilicone proliferation were the factors causing redetachment.
CONCLUSIONS: The best anatomical and functional results are obtained by dissection of the anterior membranes. In order to properly remove the retinal periphery the crystalline or intraocular lens should be removed. Comparison of our results with others indicates that anatomical success depends, to a certain extent, on doing only one, radical operation on the pathology that leads to recurrence.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11456019     DOI: 10.1177/112067210101100211

Source DB:  PubMed          Journal:  Eur J Ophthalmol        ISSN: 1120-6721            Impact factor:   2.597


  2 in total

1.  Surgical and visual outcome for recurrent retinal detachment surgery.

Authors:  Constantin Pournaras; Chrysanthi Tsika; Catherine Brozou; Miltiadis K Tsilimbaris
Journal:  J Ophthalmol       Date:  2014-08-11       Impact factor: 1.909

Review 2.  Management of recurrent rhegmatogenous retinal detachment.

Authors:  Manish Nagpal; Pranita Chaudhary; Shachi Wachasundar; Ahmed Eltayib; Aparajita Raihan
Journal:  Indian J Ophthalmol       Date:  2018-12       Impact factor: 1.848

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.